916
Views
17
CrossRef citations to date
0
Altmetric
Original Article

Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients

, , &
Pages 424-433 | Accepted 03 Jan 2012, Published online: 27 Jan 2012

Figures & data

Figure 1.  Schematic description of Markov model.

Figure 1.  Schematic description of Markov model.

Table 1.  Summary of model inputs.

Figure 2.  Relapse rate estimation.

Figure 2.  Relapse rate estimation.

Figure 3.  Disease progression estimation for EDSS 0.0–2.5 to EDSS 3.0–5.5.

Figure 3.  Disease progression estimation for EDSS 0.0–2.5 to EDSS 3.0–5.5.

Figure 4.  Disease progression estimation for EDSS 3.0–5.5 to EDSS 6.0–7.5.

Figure 4.  Disease progression estimation for EDSS 3.0–5.5 to EDSS 6.0–7.5.

Table 2.  Costs (monthly cost, €, 2010).

Table 3.  Results.

Table 4.  Sensitivity analysis results.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.